RNS Number : 5164Q

4d Pharma PLC

28 June 2022

4D pharma plc

(the "Company" or "4D pharma")

Result of AGM

At the annual general meeting of 4D pharma plc (AIM: DDDD; Nasdaq: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products, held earlier today, all resolutions put to shareholders were duly passed.

The full text of each resolution was included in the notice of the meeting, which was posted to shareholders on 20 May 2022, and is available on the Company's website www.4dpharmaplc.com .

The results for the resolutions will shortly be available on the Shareholder Information section of the Company's website, www.4dpharmaplc.com .

Ahead of the meeting, the following statement was made:

"On 24 June 2022, David Pike and James Clark of Interpath Advisory were appointed as administrators of the Company. The administrators have had no oversight of or involvement in the preparation or convening of this Annual General Meeting nor in any of the materials circulated to the Company's shareholders in advance of this Annual General Meeting [which for the avoidance of doubt shall include, [but not be limited to], the Notice of Annual General Meeting dated 25 May 2022 ("AGM Notice") or any enclosures or documents referred to therein.]

Therefore, the administrators make no statement or representation in respect of any of the matters raised or discussed in advance of or during this Annual General Meeting. The administrators make no comment whatsoever in respect of the AGM Notice including any information on the Company or its equity securities, any statements of belief or intent by the Directors, the resolutions proposed (including any recommendations given by the Directors in relation to them or reasoning for the resolutions) or which may be passed at this meeting, or any answers given by the Directors to questions raised by shareholders in connection with this Annual General Meeting. The Administrators intend to take legal advice as to whether any resolutions that are passed at the meeting are, in all circumstances, legally valid. The administrators make no comment whatsoever on the appropriateness of the convening of the Annual General Meeting or the manner in which the Annual General Meeting is conducted. To the extent that the implementation of any resolutions passed at this Annual General Meeting requires the exercise of a management power pursuant to paragraph 64(1) of Schedule B1 of the Insolvency Act 1986, the administrators have had no opportunity to consider whether such implementation is appropriate for the purposes of the administration and therefore provide no consent in this regard."

  For further information please contact: 
              4D pharma plc 
               Duncan Peyton, Chief Executive Officer 
                ir@4dpharmaplc.com                                      + 44 (0)113 895 0130 
               Singer Capital Markets - Nominated Adviser 
                and Joint Broker                                        +44 (0) 20 7496 3000 
               Philip Davies/James Fischer (Corporate Finance) 
                Tom Salvesen (Corporate Broking) 
               Bryan Garnier & Co. Limited - Joint Broker               +44 (0)20 7332 2500 
               Dominic Wilson 
               Stern Investor Relations                                 +1-212-362-1200 
               Julie Seidel 
               Image Box Communications                                 +44 (0)20 8943 4685 
               Neil Hunter/Michelle Boxall 
                neil@ibcomms.agency / michelle@ibcomms.agency 

About 4D pharma

4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D pharma has developed a proprietary platform, MicroRx(R), that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has six clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA(R) (pembrolizumab) in solid tumors, a Phase II clinical trial of MRx0518 in combination with BAVENCIO(R) (avelumab) in the first-line maintenance setting for urothelial carcinoma , a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, and Blautix(R) in irritable bowel syndrome (IBS) which has completed a successful Phase II trial. A Phase I study of MRx0005 and MRx0029 in patients with Parkinson's disease is expected to commence in 2022. Additional preclinical-stage programs include candidates for CNS disease, immune-inflammatory conditions and cancer. The Company has a research collaboration with MSD (Merck & Co., Inc., Kenilworth, NJ, USA), to discover and develop Live Biotherapeutics for vaccines.

For more information, refer to https://www.4dpharmaplc.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

June 28, 2022 10:15 ET (14:15 GMT)

4d Pharma (LSE:DDDD)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more 4d Pharma Charts.
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more 4d Pharma Charts.